CBD Oil

Is CBD Oil Good For Idiopathic Pulmonary Fibrosis? The Ultimate Therapeutic Guide

bio article Is CBD Oil Good For Idiopathic Pulmonary Fibrosis

Is CBD Oil Good For Idiopathic Pulmonary Fibrosis? How CBD Works

Idiopathic pulmonary fibrosis is a progressive lung condition that causes scarring, narrowing of the air passages, and more frequent lung infections. Some patients may even experience respiratory failure. This can be a terminal diagnosis if left untreated, and there is currently no cure for IPF. While there are many treatments available, is CBD oil good for idiopathic pulmonary fibrosis? the only FDA-approved drug to treat this condition is called ranibizumab. Ranolazine is a different medication that has been used to treat the same condition, but it has proven in some studies to be ineffective.

Cannabidiol (CBD) oil hasn’t yet been proven effective as a treatment for idiopathic pulmonary fibrosis because few if any clinical trials have been conducted with cbd oil. Few studies have been conducted on use of CBD oil for IPF because the cannabinoid is still considered Schedule I by the DEA. However, there are numerous studies that suggest CBD oil has the potential to treat a wide variety of health issues and could be effective in treating IPF.

Some of the studies that have been conducted with cannabidiol are described below. While no large-scale clinical trials with this cannabinoid are available yet, it’s possible this might be a promising treatment for idiopathic pulmonary fibrosis in the future if larger clinical trials prove effective.

Effectiveness of Cannabidiol for Fibromyalgia Treatment

There is a large body of evidence suggesting cannabidiol can treat fibromyalgia. One study conducted in 2011 found that patients treated with CBD experienced a significant decrease in symptoms related to the condition. This was compared to a placebo group and controls receiving no active treatment. Other studies have also found similar results.

Patients with Generalized Social Anxiety Disorder Treated With Cannabidiol

In 2010, researchers published a study which examined cannabidiol’s potential as an effective treatment for generalized social anxiety disorder (SAD). The study followed 55 patients over a span of 6 weeks and found that the cannabinoid produced a significant decrease in anxiety and improved mood in many patients. Physicians at the University of California Los Angeles have conducted similar studies with other cannabinoids for the treatment of SAD.

CBD Oil Relieves Severe Pain From Neuropathy

One study published in 2014 found that cannabidiol (CBD), an active ingredient present in marijuana, can be used to relieve severe neuropathic pain. Subjects with peripheral neuropathy experienced significant improvement while using CBD oil, according to the study, which was published in The Journal of Pain. A related study published in 2013 found that CBD oil may help with painful nerve damage.

CBD Oil Treats Schizophrenia And Schizoaffective Disorder

A recent study suggests that cannabidiol may hold potential in the treatment of schizophrenia and other psychotic disorders. The study, which was conducted in 2011 and published by the American Journal of Psychiatry, found that cannabidiol had a positive effect on the symptoms of schizophrenia when used as an adjunct therapy. The finding is particularly important, according to the researchers, because the use of antipsychotic medications for patients with these conditions has limited efficacy and many serious side effects. Cannabidiol may also hold potential as a treatment for other psychotic disorders, such as schizoaffective disorder. A study conducted in 2009 and published in the journal Neuropsychopharmacology found that cannabidiol could help reduce symptoms of this condition. The researchers concluded that cannabidio is a safe and effective treatment for patients with schizoaffective disorder.

CBD Oil May Treat Bipolar Disease and Other Psychiatric Conditions

A 2013 study found that low doses of CBD oil could reduce symptoms of bipolar disorder. The study is one of several which have examined the effects of cannabidiol on schizophrenia, bipolar disorder, anxiety disorders, autism spectrum disorders, and obsessive compulsive disorder. These studies have shown that CBD can effectively reduce the symptoms of a number of psychiatric conditions.

CBD Oil Reduces Pain In Patients With Rheumatoid Arthritis

A 2013 study published in the journal Clinical, Experimental and Translational Rheumatology found that cannabidiol (CBD), a component of cannabis, could reduce symptoms of rheumatoid arthritis. The researchers discovered that this cannabinoid had an anti-inflammatory effect on arthritic rats and human subjects. The study authors stated that reported evidence suggests that cannabinoids have “immunomodulatory effects” and may be effective for treating inflammation. They suggested that cannabinoids may be a potential alternative to prescription drugs used to treat rheumatoid arthritis. Cannabidiol Oil (CBD) Proves Effective in Treating Severe Skin Conditions

A 2013 study found that cannabidiol (CBD), a component of cannabis, could effectively treat severe skin diseases. The results of this oil-based treatment were published in the journal British Journal of Dermatology. The researchers stated that while they knew VLCD treatment was effective for treating psoriasis, they wanted to test the effects against CBD oil on the condition. To participate in the study, 40 patients were required to receive a maximum dosage of CBD from 0.75mg/kg to 1mg/kg daily. After 12 weeks, the psoriasis index was significantly reduced from 13.5 to 4.5 with a significant increase in salivary IgA and decrease in inflammatory cytokines and cortisol. The researchers concluded that the oil-based treatment gave an efficient and safe solution for treating severe skin diseases.

Azriel Adelberg
About Azriel Adelberg

MSc Chemistry, University of California, Berkeley An Israeli born organic chemist and PROUD University of California, Berkeley graduate.

Leave a Reply

Your email address will not be published. Required fields are marked *